1 research outputs found

    Henoch-Schönlein purpura in adulthood

    Get PDF
    Background: Henoch-Schonlein purpura (HSP) is a systemic inflammation of small-vessel walls that predominantly affects children. In adults, on the other hand, it appears rarely, and can be more severe. The disease is characterised by a tetrad of clinical signs which manifest the skin, joint, gastrointestinal, and kidney involvement. HSP is diagnosed using internationally-accepted criteria. At present, there is no effective specific therapy for children and adults. However, in cases of severe organ involvement, aggressive treatment may stabilise the disease. Case report: We present a case of a 59-year-old immunologically uncom- promised patient with an extremely severe form of HSP. Epidemiology, etiopathogenesis, clinical features, diagnostic procedures, differential diagnosis, treatment, and prognosis of the disease are discussed. Conclusions: The patient was treated with corticosteroids, human polyspecific immunoglobulins, and immunosuppressive agents. A satisfactory clinical remission has been achieved.Izhodišča: Henoch-Schonleinova purpura (HSP) je sistemsko vnetje sten malih žil, ki najpogosteje prizadene otroke. Odrasli obolijo redko, potek bolezni pa je pri njih lahko življenjsko ogrožujoč. Za HSP je značilna tetrada kliničnih znakov, ki zrcali okvaro kože, sklepov, prebavnega trakta in ledvic. Pri postavitvi diagnoze je potrebno upoštevati zastavljena diagnostična merila. Učinkovito specifično zdravljenje bolezni pri otrocih in odraslih še ne obstaja. Kljub temu pa je pri težjem poteku z agresivnejšim terapevtskim pristopom možno doseči stabilno klinično sliko. Prikaz primera: Predstavljen je primer 59-letnega imunsko neprizadetega bolnika, pri katerem je bila potrjena izjemno težka oblika HSP. Razpravljamo o epidemiologiji, etiopatogenezi, klinični sliki, diagnostičnih postopkih, diferencialni diagnozi, zdravljenju in prognozi te bolezni. Zaključki: Pri bolniku je bilo uvedeno zdravljenje s kortikosteroidi, humanimi polispecifičnimi imunoglobulini ter citostatiki. Doseženo je bilo zadovoljivo začasno izboljšanje bolezni
    corecore